Autopsy report · NCT00969917

Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

“Company decision not to start the study”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Infinity Pharmaceuticals, Inc.

Sponsor type

Industry

Conditions

Dedifferentiated Liposarcoma

Interventions

IPI-504

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis
  “Company decision to not conduct study” (85% match in meaning)
• Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia
  “Company decision to halt study” (80% match in meaning)
• SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
  “The study was terminated early due to company decision” (78% match in meaning)
• A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
  “Business decision to stop the study.” (76% match in meaning)
• Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.
  “Study is withdrawn due to company decision.” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.